[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342970-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342970-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-potential-of-cul3-ligase-with-differential-roles-in-luminal-a-and-basal-type-breast-cancer-tumors-research-summary","Prognostic potential of CUL3 ligase with differential roles in luminal A and basal type breast cancer tumors - Research summary","","Prognostic potential of CUL3 ligase is investigated in breast cancer, emphasizing how its roles differ across luminal A and basal-type tumors. The study connects breast cancer heterogeneity and molecular subtypes with the ubiquitin–proteasome pathway, focusing on CUL3 as a candidate biomarker. High-throughput sequencing and gene expression profiling are combined with database analyses using GEPIA2, UALCAN, and TCGA datasets to evaluate CUL3 expression and prognostic relevance. Functional and localization studies in MCF-7 and MDA-MB-231 cells, along with tissue profiling, reveal tumor-type dependent effects linked to cell-cycle progression and DNA damage response.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-potential-of-cul3-ligase-with-differential-roles-in-luminal-a-and-basal-type-breast-cancer-tumors-research-summary/342970/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-potential-of-cul3-ligase-with-differential-roles-in-luminal-a-and-basal-type-breast-cancer-tumors-research-summary/342970.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of the study about CUL3 ligase in breast cancer?","Question",{"text":63,"@type":64},"The study evaluates CUL3 as a potential biomarker and examines how its functional roles vary between luminal A and basal-type breast cancer tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were CUL3 expression and prognostic value assessed?",{"text":68,"@type":64},"CUL3 expression and its association with prognosis were analyzed using high-throughput sequencing and gene expression profiling, supported by database tools including GEPIA2, UALCAN, and TCGA datasets.",{"name":70,"@type":61,"acceptedAnswer":71},"What biological processes are associated with CUL3 in different tumor types?",{"text":72,"@type":64},"The study links CUL3 to cell-cycle progression and DNA damage response, showing distinct effects depending on the tumor’s molecular subtype.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342970,1790188731,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPrognostic potential of CUL3 ligase with differential roles in luminal A and basal type breast cancer tumors  \nVasiliki Pantazi1,2,3, Vanda Miklós1, Paul Smith4, Orsolya Oláh‑Németh1,2,  \nGabriella Pankotai‑Bodó2, DivyaTeja Dondapati 5, FerhanAyaydin5, Vincenzo D’Angiolella4 & Tibor Pankotai1,2,3*  \nBreast cancer is a prevalent and significant cause of mortality in women, and manifests as six molecular subtypes. Its further histologic classification into non‑invasive ductal or lobular carcinoma (DCIS) and invasive carcinoma (ILC or IDC) underscores its heterogeneity. The ubiquitin–proteasome system plays a crucial role in breast cancer, with inhibitors targeting the 26S proteasome showing promise in clinical treatment. The Cullin‑RING ubiquitin ligases, including CUL3, have direct links to breast cancer. This study focuses on CUL3 as a potential biomarker, leveraging high‑throughput sequencing, gene expression profiling, experimental and data analysis tools. Through comprehensive analysis using databases like GEPIA2 and UALCAN, as well as TCGA datasets, CUL3’s expression and its association with prognostic values were assessed. Additionally, the impact of CUL3 overexpression was explored in MCF‑7 and MDA‑MB‑231 breast cancer cell lines, revealing distinct differences in molecular and phenotypic characteristics. We further profiled its expression and localization in breast cancer tissues identifying prominent differences between luminalA and TNBC tumors. Conclusively, CUL3 was found to be associated with cell cycle progression, and DNA damage response, exhibiting diverse roles depending on the tumor’s molecular type. It exhibits a tendency to act as an oncogene in triple‑negative tumors and as a tumor suppressor in luminalA types, suggesting a potential significance in breast cancer progression and therapeutic directions.  \nBreast cancer (BRCA) stands as one of the most prevalent cancer types, ranking as the second leading cause of death among women. According to the American Cancer Society’s projections for 2023, approximately 297,790 new cases of invasive breast cancer and 55,000 cases of ductal carcinoma are expected to be diagnosed in women1. In recent years, incidence rates have shown a 0.5% annual increase, and on average, a woman in the United States faces a 13% lifetime risk of developing breast cancer. This means that 1 out of 8 women will be diagnosed with breast cancer at some point in their lives1.  \nBreast cancer exhibits a diverse nature with six distinct molecular subtypes: luminal A [characterized by progesterone receptors (PR+), estrogen receptor (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)−, and Ki67−], luminal B (ER+, HER2±, and Ki67+), HER2-positive, basal-like subtype (ER−, PR−, and HER2−, also known as Triple Negative Breast Cancer or TNBC), normal breast-like, and claudin-low type2,3. Alternatively, based on histologic type, breast cancer is classified as ductal or lobular carcinoma in situ (DCIS), a non-invasive or pre-invasive carcinoma, and invasive carcinoma (ILC or IDC), which involves spreading into the surrounding breast tissue2. While ductal carcinoma in situ (DCIS) represents an intermediate phase of breast cancer and is not immediately life-threatening, it does pose a risk of progressing to invasive breast cancer (IBC)4. DCIS is estimated to constitute around 20% of diagnosed breast cancers in the United States, and it is believed that 14–50% of DCIS  \n1Genome Integrity and DNA Repair Core Group, Hungarian Centre of Excellence for Molecular Medicine (HCEMM), Szeged, Hungary. 2Department of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary. 3Competence Centre of the Life Sciences Cluster of the Centre of Excellence for Interdisciplinary Research, Development and Innovation, University of Szeged, Szeged, Hungary. 4The Institute of Genetics and Cancer, University of Edinburg","cbCaihr5XtnLRkxC","https://ap.wps.com/l/cbCaihr5XtnLRkxC","pdf",10364347,"English","# Background and rationale\n## Breast cancer heterogeneity and subtypes\n## Ubiquitin–proteasome system and CUL3\n# Methods\n## Gene expression and high-throughput sequencing\n## Database and TCGA analyses (GEPIA2, UALCAN)\n## Cell line and tissue studies\n# Findings\n## CUL3 expression and prognostic associations\n## Differential roles in luminal A vs basal-type tumors\n## Links to cell cycle and DNA damage response\n# Conclusions and implications\n## Oncogenic vs tumor-suppressive behavior by molecular type","[{\"question\":\"What is the main focus of the study about CUL3 ligase in breast cancer?\",\"answer\":\"The study evaluates CUL3 as a potential biomarker and examines how its functional roles vary between luminal A and basal-type breast cancer tumors.\"},{\"question\":\"How were CUL3 expression and prognostic value assessed?\",\"answer\":\"CUL3 expression and its association with prognosis were analyzed using high-throughput sequencing and gene expression profiling, supported by database tools including GEPIA2, UALCAN, and TCGA datasets.\"},{\"question\":\"What biological processes are associated with CUL3 in different tumor types?\",\"answer\":\"The study links CUL3 to cell-cycle progression and DNA damage response, showing distinct effects depending on the tumor’s molecular subtype.\"}]","Prognostic potential of CUL3 ligase with differential roles in luminal A and basal type breast cancer tumors - Research summary | PDF",1790049196,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef8cf7499193b7868a7ae37c116f4aa9.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/956ecf41bc3ee7d48d03fef715632717.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cfc41beabf1ecf2de5080201c7dec58.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/747b4c68d85f75fb64e1c4c127cf90e4.webp",980,1287]